Once your product is approved, will you be ready to go to market?
For emerging pharma companies, it can be a challenge to stay on top of everything that needs to be done to bring a new drug to the market. From clinical trials to finally obtaining FDA approval, it’s an arduous process that involves a lot of moving parts.
In the midst of going through this process, it can be easy to lose sight of your channel strategy. In many cases, the executives of emerging pharma companies have come from big pharma where they had teams of people who focused on channel management, as well as matters like compendia submissions and EHRx strategy. But now, with a much smaller team and fewer resources, they often find themselves unprepared to go to market once their drug is approved.